Education
Ph. D. (1991) University of Virginia, Department of Chemistry.
B.S. (1982) Wuhan University, Department of Chemistry, PR China
Professional Experience
CEO and Founder: XW Laboratories Inc. (07/13 - present)
Senior Director: Head of Integrated Platform Science, GSK China R&D Center (03/12 – 07/13)
Member: Executive Leadership Team, GSK China R&D Center (12/07 – 07/13)
Senior Director: Medicinal Chemistry, GSK China R&D Center (12/10 – 02/12)
Director: Medicinal Chemistry, GSK China R&D Center (11/07 – 11/10)
Director: Medicinal Chemistry, XenoPort, Inc. (05/01 - 10/07)
Project Director: XenoPort - Alza, Johnson & Johnson collaboration (12/02 - 3/05)
Assistant Director: Medicinal Chemistry, Upper Merion, GlaxoSmithKline (11/00 - 04/01)
Project Liaison: GSK - Shanghai Institute of Meteria Medica collaboration (09/97 - 04/01)
Senior Investigator: Medicinal Chemistry, Upper Merion, SmithKline Beecham (12/96 - 11/00)
Investigator: Medicinal Chemistry, Upper Merion, SmithKline Beecham (12/92 - 12/96)
Postdoctoral Fellow: California Institute of Technology (10/90 - 12/92).
Research project: Total synthesis of Neocarzinostan aglycon. Advisor: Andrew G. Myers
Predoctoral Fellow: Yale Medical School, Department of Pharmacology (1/85 - 8/86).
Research project: Synthesis 3'-Azido Analogues of Pyrimidine Deoxyribonucleosides against Human Immunodeficiency Virus (HIV-1, HTLV-III/LAV). Advisor: Tai-Shun Lin
Research Associate: Hubei Institute of Chemistry, Wuhan, PR China (8/82 - 12/84)
